Abstract

Since the discovery, over a decade and a half ago, that genetically engineered DNA can be delivered in vaccine form and elicit an immune response, there has been much progress in understanding the basic biology of this platform. A large amount of data has been generated in preclinical model systems, and more sustained cellular responses and more consistent antibody responses are being observed in the clinic. Four DNA vaccine products have recently been approved, all in the area of veterinary medicine. These results suggest a productive future for this technology as more optimized constructs, better trial designs and improved platforms are being brought into the clinic.

Author affiliations

1. Division of Infectious Diseases and HIV Medicine, The Department of Medicine, Drexel University College of Medicine, 245 North 15th Street, Philadelphia, Pennsylvania 19102, USA.
2. The Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, 422 Curie Boulevard, Philadelphia, Pennsylvania 19104, USA.

Correspondence to: David B. Weiner² Email: dbweiner@mail.med.upenn.edu

MORE ARTICLES LIKE THIS

These links to content published by NPG are automatically generated.